THERABEST Japan, Inc., Kobe, Japan.
Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Front Immunol. 2022 Jul 8;13:890894. doi: 10.3389/fimmu.2022.890894. eCollection 2022.
Natural killer (NK) cell immunotherapies for cancer can complement existing T cell therapies while benefiting from advancements already made in the immunotherapy field. For NK cell manufacturing, induced pluripotent stem cells (iPSCs) offer advantages including eliminating donor variation and providing an ideal platform for genome engineering. At the same time, extracellular vesicles (EVs) have become a major research interest, and purified NK cell extracellular vesicles (NKEVs) have been shown to reproduce the key functions of their parent NK cells. NKEVs have the potential to be developed into a standalone therapeutic with reduced complexity and immunogenicity compared to cell therapies. This review explores the role iPSC technology can play in both NK cell manufacturing and NKEV development.
自然杀伤 (NK) 细胞免疫疗法可用于癌症治疗，与现有的 T 细胞疗法相辅相成，同时还能受益于免疫疗法领域的已有进展。对于 NK 细胞的制造，诱导多能干细胞 (iPSC) 具有诸多优势，包括消除供体差异，为基因组工程提供理想平台。与此同时，细胞外囊泡 (EV) 已成为主要研究热点，经证实，纯化的 NK 细胞细胞外囊泡 (NKEV) 可再现其亲本 NK 细胞的关键功能。与细胞疗法相比，NKEV 具有开发为更简单、免疫原性更低的独立治疗方法的潜力。本综述探讨了 iPSC 技术在 NK 细胞制造和 NKEV 开发中的作用。
